ImmunityBio posts Q2 2026 revenue of $50.7 million as ANKTIVA pipeline advances
The company reported its eighth straight quarter of sequential product revenue growth and disclosed new regulatory and supply milestones for ANKTIVA.
SEC filing
Latest
4 stories
Tuesday, August 25
Monday, August 10
Washington University registers Phase Ib trial pairing Sip-T with N-803 in resistant prostate cancer
Tuesday, August 4
Thursday, July 30
ImmunityBio wins UAE authorization for ANKTIVA in bladder cancer and lung cancer
The Emirates Drug Establishment cleared ANKTIVA for BCG-unresponsive bladder cancer and metastatic NSCLC, marking the drug's 34th country authorization.
SEC filing